Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RHAPSODY phase 3 trial of rilonacept for recurrent pericarditis
MOH_2019-03-24_006045Phase 3Not yet recruiting
- Sponsor
- Kiniksa Pharmaceuticals
- Start
- Feb 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in recurrent pericarditis comparing Rilonacept once weekly with Matching placebo once weekly (2 arms). Primary endpoint: Primary efficacy endpoint. Planned start Feb 2019; status: not yet recruiting.
02
Drugs
rilonacept
03
Conditions
recurrent pericarditis
Beyond the preview
Go deeper on MOH_2019-03-24_006045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-03-24_006045.